Full metadata record
DC FieldValueLanguage
dc.contributor.authorHo, Shu-Yien_US
dc.contributor.authorChang, Bo-Hauen_US
dc.contributor.authorChung, Chen-Hanen_US
dc.contributor.authorLin, Yu-Lingen_US
dc.contributor.authorChuang, Cheng-Hsunen_US
dc.contributor.authorHsieh, Pei-Jungen_US
dc.contributor.authorHuang, Wei-Chihen_US
dc.contributor.authorTsai, Nu-Manen_US
dc.contributor.authorHuang, Sheng-Chiehen_US
dc.contributor.authorLiu, Yen-Kuen_US
dc.contributor.authorLo, Yu-Chihen_US
dc.contributor.authorLiao, Kuang-Wenen_US
dc.description.abstractBackground: Gene therapy is a potent method to increase the therapeutic efficacy against cancer. However, a gene that is specifically expressed in the tumor area has not been identified. In addition, nonspecific expression of therapeutic genes in normal tissues may cause side effects that can harm the patients' health. Certain promoters have been reported to drive therapeutic gene expression specifically in cancer cells; however, low expression levels of the target gene are a problem for providing good therapeutic efficacy. Therefore, a specific and highly expressive promoter is needed for cancer gene therapy. Methods: Bioinformatics approaches were utilized to analyze transcription factors (TFs) from high-throughput data. Reverse transcription polymerase chain reaction, western blotting and cell transfection were applied for the measurement of mRNA, protein expression and activity. C57BL/6JNarl mice were injected with pD5-hrGFP to evaluate the expression of TFs. Results: We analyzed bioinformatics data and identified three TFs, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B), cyclic AMP response element binding protein (CREB), and hypoxia-inducible factor-1 alpha (HIF-1 alpha), that are highly active in tumor cells. Here, we constructed a novel mini-promoter, D5, that is composed of the binding sites of the three TFs. The results show that the D5 promoter specifically drives therapeutic gene expression in tumor tissues and that the strength of the D5 promoter is directly proportional to tumor size. Conclusions: Our results show that bioinformatics may be a good tool for the selection of appropriate TFs and for the design of specific mini-promoters to improve cancer gene therapy.en_US
dc.subjectGene therapyen_US
dc.subjectTranscription factoren_US
dc.subjectHIF-1 alphaen_US
dc.subjectNF-kappa B and CREBen_US
dc.titleDevelopment of a computational promoter with highly efficient expression in tumorsen_US
dc.identifier.journalBMC CANCERen_US
dc.contributor.departmentCollege of Biological Science and Technologyen_US
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.contributor.departmentInstitute of Molecular Medicine and Bioengineeringen_US
dc.contributor.departmentCenter for Bioinformatics Researchen_US
Appears in Collections:Articles